New Faculty Research Award for Early Career Researchers (ECRs)

New Faculty Research Award for Early Career Researchers (ECRs)

Funding up to $10,000 is available for new recruits in the UBC Faculty of Medicine.

The New Faculty Research Award is for faculty in the first two years of their first full-time appointment as Assistant Professor and higher, or a Clinical faculty appointment as Clinical Assistant Professor and higher. The funds may be used for research equipment, research supplies and/or research services, and research support salaries.

Application evaluation criteria:

  • Potential and quality of the proposed research
  • Proposed use and impact of the funds
  • Applicant’s time devoted to research
  • Applicant’s scholarly productivity in the context of the career stage and personal circumstances
  • Applicant’s competitiveness for external funding

Determine whether you’re eligible, and learn more about the criteria for use of funds, and view instruction information here

Application Deadline: 26 June 2023 | 5pm

Government of Canada invests in high-risk, high-reward interdisciplinary research to support world-leading innovation

Investments will support close to 200 game-changing research projects and cement Canada’s position as a leader in science and innovation.

The Government of Canada has announced that it will be supporting interdisciplinary work that drives innovation by Canadians to impact wellbeing of society from a health perspective as well as a wellness perspective.

NFRF = New Frontiers in Research Fund

There are 3 key aspects of the investment:

  1. NFRF 2022 Transformation Competition
    • This will fund interdisciplinary projects that are large-scale and focus on major challenges.
    • Examples of topics include overcoming cardiovascular diseases; building an innovative open science platform for neuroscience drug discovery; developing non-invasive cancer therapy; improving patient care for the treatment of neurological disorders; creating a renewable energy seasonal storage solution; and ensuring artificial intelligence is inclusive of Indigenous knowledge systems.
  2. NFRF 2022 Special Call
    • This call will support 61 research teams to conduct research on post pandemic recovery, as part of an international approach to impact Covid-19 pandemic-induced inequities.
  3. NFRF 2022 Exploration Competition
    • A total of 128 research projects will be funded through this competition. Projects should demonstrate interdisciplinary work in novel ways to ensure there diverse perspectives driving innovation.
    • Examples of topics include training artificial intelligence models to detect medical bias experienced by marginalized communities; developing a self-powered nanocomposite filter for point-of-use drinking water treatment in First Nations communities; and using aeromicrobiology as an innovative approach to greenhouse gas mitigation

“The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, announced more than $200 million in support for Canadian-led interdisciplinary, international, high-risk and high-reward research through the New Frontiers in Research Fund (NFRF). Through three different NFRF competitions, the government will support 195 projects.”

These investments are promising, as they demonstrate the crucial need that Canada has to generate and support new strategies and tactics for disciplines to work together, with the outcome of providing incredibly successful breakthroughs.

Read the announcement in full here

Good Read: The New Era of Life Sciences

Government of Canada Improves Access to Affordable and Effective Drugs for Rare Diseases

The Government of Canada has made an announcement which will benefit the 1 in 12 people (many of whom are children) living with a rare disease in the country.

The Government of Canada will support the National Strategy for Drugs for Rare Diseases, which is the first of its kind. The purpose of this strategy is to “help increase access to, and affordability of, effective drugs for rare diseases to improve the health of patients across Canada, including children”. The investment will include up to $1.5 billion over three years. The Non-Insured Health Benefits Program (NIHB) at Indigenous Services Canada will also receive $33 million in new investments.

Despite there being thousands of such rare diseases affecting many individuals and their support systems, only a small percentage of conditions have treatments available. Of those who may benefit from the effectiveness of these treatments in their quality of living, many patients are unfortunately still restricted from utilizing the medications due to significant financial barriers and limited access.

This strategy is promising, as it shows a national commitment towards providing Canadians with rare diseases with the drugs they need in both a timely manner and at a reasonable price. In addition, the early diagnosis and screening for rare diseases will improve.

The announcement can be found here in full with associated links (for example: Regulatory innovation for health products). It also includes the following quick facts:

  • Innovative treatments for rare disease can cost anywhere from $100,000 to more than $2 million per year. Budget 2019 provided funding up to $1 billion over two years, with up to $500 million per year ongoing, to help Canadians with rare diseases access the drugs they need.
  • In July 2021, Health Canada released a What We Heard Report from national engagement on the National Strategy. The engagement garnered diverse perspectives from over 650 individuals and organizations, including patients with lived experience, family members, and caregivers.
  • In December 2022, Health Canada pre-published proposed amendments to the Food and Drug Regulations that would introduce regulatory flexibilities such as the option of a rolling review, which may facilitate earlier market access for certain drugs, including drugs for rare diseases. The proposal would also allow for terms and conditions for all drugs, enabling Health Canada to include obligations on the manufacturer to optimize the benefits and manage any risks and uncertainties associated with the drug. This would be particularly important in the cases of drugs for rare diseases where patient populations are small.
  • Additionally, Health Canada’s Pediatric Drug Action Plan aims to improve access to safe and effective medicine for children in Canada, including drugs for rare diseases, which tend to be more prevalent in the pediatric population.

Catrina Loucks

Catrina Loucks

Title: Assistant Professor and Investigator

Department and Affiliations: 

Department of Pediatrics

Department of Anesthesiology, Pharmacology & Therapeutics

BC Children’s Hospital Research Institute

Location: BC Children’s Hospital Research Institute

Tell us about your research and what makes you passionate about it.

Research in my lab is working to discover how our individual genetic differences can influence how likely we are to develop painful conditions, experience severe pain, and respond to different pain relievers. Our research is so exciting to us because we have the opportunity to help vulnerable populations such as children with cancer who experience high levels of pain not only from their disease but from their life-saving medications.

Is there a translational aspect of your research that you are most excited about?

Our work starts with genetic discovery and progresses to the clinical implementation of pharmacogenomic testing to help design personalized pain management strategies to optimize pain relief without harm. This translational aspect is so important because young children are often unable to communicate their levels of pain and whether their pain is relieved. Therefore, predictive genetic testing offers a way to help identify pain relievers that are most likely to be safe and effective for them.

Are there any initiatives you would like to see at UBC to accelerate translational medicine in your area of research?

As a PhD-trained scientist, I rely on developing strong collaborations with clinical colleagues in order to identify research priorities that will deliver value to patients and families. I also rely on these collaborations to translate our genetic findings into pharmacogenomic testing strategies. I would love to see more initiatives that aim to formalize/initiate these sorts of connections (e.g., matchmaking opportunities).

You are part of the Academy of Translational Medicine Early Career Researcher cohort at UBC. What is the most important aspect of that community for you?

This community provides a wonderful opportunity to present translational work to varied audiences, and to hear about the varied translational work of others, so that necessary interdisciplinary aspects can be considered to improve the quality of research outputs.

Is there a resource that you found impactful and would recommend to others interested in translational medicine?

I am fortunate to be supported by the amazing people at the Research & Technology Development Office at the BC Children’s Hospital Research Institute who have helped me immensely in both the strategic development of my research program as well as dramatically improving my research grant submissions.

How do you like to recharge outside of work?

I like to spend time with my family. Since my children are still small, this generally means spending time at the park, making crafts or having silly dance parties.

Applications Now Open for the 2023/2024 Creative Destruction Lab Program

Creative Destruction Lab (CDL) has announced that application are open for the 2023/2024 Program Year. This will be CDL’s 12th cohort.

The 9-month program is intended for founders, and includes 5 meetings. Throughout the program, participants are provided mentorship from tech entrepreneurs with excellence in founding, leading, and selling their companies. Skills such as setting objectives are emphasized, to help companies prioritize important aspects of their company while cutting through distractions.

The program is unique with no fees for founders, and CDL takes no equity. The program has 20 different streams in 12 locations, split across Canada, the USA, and Europe. CDL Vancouver is 1 of 5 Canadian sites.

The Application Deadline for the 2023/2024 Program Year is July 28th 2023


Read about CDL and the program

View the announcement 

Attend a CDL 15-minute Intro Webinar in May

Apply for the program

BC announces a new Life Sciences and Biomanufacturing Strategy

The ATM is pleased to hear that British Columbia has announced a new Life Sciences and Biomanufacturing Strategy as part of the StrongerBC Economic Plan.

The Life Sciences and Biomanufacturing Strategy will secure B.C.’s position as a leading global hub for life sciences and biomanufacturing and develop commercial-scale biopharmaceutical and medical manufacturing. By consciously investing in people and infrastructure, the province will tapping into the potential of the industry value chain spanning the timeline from discovery to clinical trials and manufacturing.

Part of this plan plan is to target local companies focused on innovation. For example, the province is investing $10 in a new adMare Bioinnovations wet lab facility with cutting-edge equipment. Together with announcements such as the National Biomanufacturing Training Centre (NBTC), the provincial commitment to excellence in the life science sector is prominent. The Academy of Translational Medicine is excited to hear about the announcement of the Life Sciences and Biomanufacturing Strategy and what it will mean for translational medicine efforts in the province.

“The launch of the B.C. Life Sciences and Biomanufacturing Strategy is a significant step toward improving health care and patient outcomes by investing in clinical trials capacity. By expanding B.C.’s clinical trials capacity, we are creating opportunities for more innovative companies to anchor and grow in B.C., which will benefit patients by increasing access to new treatments and therapies.” – Adrian Dix, Minister of Health.

Read the announcement here and watch the video below!

Aspect Biosystems and Novo Nordisk Enter Partnership to Develop Bioprinted Tissue Therapeutics for Diabetes and Obesity

Aspect Biosystems and Novo Nordisk A/S recently announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity.

This partnership allows Aspect and Novo Nordisk to join the proprietary bioprinting technology from Aspect with the expertise and technology that Novo Nordisk has in stem cell differentiation and cell therapy development and manufacturing. 

As a result of this agreement, Aspect is providing Novo Nordisk with an exclusive, worldwide licence. The license will allow Novo Nordisk to develop up to four products, with the purpose of treating diabetes and/or obesity.In return, Aspect will receive $75 million USD in associated initial payments, plus eligibility for $650 million USD in future development, regulatory, commercial and sales milestone payments per product, as well as tiered royalties on future product sales.

This announcement demonstrates the amplified potential for medical breakthroughs and therapeutics that come with collaborative work.

Read more about the announcement here

Applications Open: 2023 Convening & Collaborating (C2) and Reach Programs

The Michael Smith Health Research BC 2023 Convening & Collaborating (C2) and Reach awards are now open.

These awards are an exciting opportunity for translational medicine. Each offers up to $15,000 for a term of 18 months, targeting knowledge translation (KT) work to help propel research towards use in policy and in practice. The awards are co-funded by numerous organizations in order to provide funding to a larger number of recipients and increase the impact of the awards.

Convening & Collaborating (C2) Awards

The C2 award enables knowledge exchange and meaningful collaboration by supporting researchers, trainees and research users* in co-developing research that can directly impact people such as patients, health practitioners and policy makers, helping to ensure the research’s relevancy. 

Details specific to the Convening & Collaborating (C2) Awards can be found here

Reach Awards

The Reach award enables KT activities by supporting researchers and research users in disseminating research evidence through co-developing events, activities and/or tools to extend the reach of their work.

Details specific to the Reach Awards can be found here

Key Dates:

  • September 2023: Anticipated notice of funding decision
  • October 1st, 2023: Anticipated start of funding

Further Information:

  • Read examples of past projects in the announcement here
  • Find full details about the competitions, application process, and more here

Nominations Open: 2023 Faculty of Medicine Awards

The Faculty of Medicine is now accepting nominations for the 2023 Faculty of Medicine Awards.

The awards acknowledge outstanding faculty and staff members who demonstrate exceptional contributions to the Faculty of Medicine, and who are dedicated to advancing the Faculty’s values and vision of transforming health for everyone.

Each award is classified under one of the following categories:

  • Lifetime Achievement
  • Mentoring
  • Staff
  • Clinical Faculty
  • Continuing Professional Development

View the full list of awards as well as their information and nomination forms.

The deadline to submit nominations is Friday June 9th, 2023